Synergy Pharmaceutical shares are trading higher after Health Canada accepted Cipher Pharmaceuticals' new drug submission for PLECANATIDE; Cipher in February acquired the Canadian rights to PLECANATIDE from Synergy.
Benzinga Newsdesk